123531-54-4

Basic information

• Product Name: 6-CHLORO-IMIDAZO[1,2-B]PYRIDAZINE-3-CARBONITRILE
• Synonyms: 6-CHLORO-IMIDAZO[1,2-B]PYRIDAZINE-3-CARBONITRILE;IMidazo[1,2-b]pyridazine-3-carbonitrile,6-chloro-;6-chloroimidazo[1,2-a]pyrazine-3-carbonitrile
• CAS NO: 123531-54-4
• Molecular Formula: C₇H₃ClN₄
• Molecular Weight: 178.58
• Mol File: 123531-54-4.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 6-CHLORO-IMIDAZO[1,2-B]PYRIDAZINE-3-CARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-CHLORO-IMIDAZO[1,2-B]PYRIDAZINE-3-CARBONITRILE(123531-54-4)
• EPA Substance Registry System: 6-CHLORO-IMIDAZO[1,2-B]PYRIDAZINE-3-CARBONITRILE(123531-54-4)

Safety Data

• Hazardous Substances Data: 123531-54-4(Hazardous Substances Data)

Usage

General Description

6-Chloro-imidazo[1,2-b]pyridazine-3-carbonitrile is a chemical compound noted for its complex structure. It belongs to the class of compounds known as heterocyclic compounds, specifically the category containing a pyridazine ring, which is a six-member aromatic ring made up of four carbon atoms and two nitrogen atoms. The molecular formula of this compound is C8H3ClN4. Its systematic name is 6-Chloro-1H-imidazo[1,2-b]pyridazine-3-carbonitrile. This indicates the presence of other functional groups in the compound, such as the chloro group, the imidazo group and the carbonitrile group, which could influence its chemical behavior and reactions.

Upstream product

• 106-96-7 propargyl bromide 
• 590-17-0 cyanomethyl bromide 
• 35053-55-5 N'-(6-chloropyridazin-3-yl)-N,N-dimethylmethanimidamide 
• 35053-54-4 N,N-dimethyl-N'-pyridazin-3-yl-formamidine 

Downstream Products

• 1150566-80-5 6-(3,4-dichloro-benzylamino)-imidazo[1,2-b]pyridazine-3-carbonitrile 
• 1365214-49-8 6-[(2R)-4,4-difluoro-2-(3-fluorophenyl)pyrrolidin-1-yl]imidazo[1,2-b]pyridazine-3-carboxamide 
• 1365214-50-1 {6-[(2R)-4,4-difluoro-2-(3-fluorophenyl)pyrrolidin-1-yl]imidazo[1,2-b]pyridazin-3-yl}carbonylurea 

Relevant articles and documents

Synthesis method of 6-chloroimidazo[1, 2-b]pyridazine-3-carbonitrile

The invention relates to a synthesis method of 6-chloroimidazo[1, 2b]pyridazine-3-carbonitrile, which comprises the following steps of 1, adding N, N-dimethylformamide dimethyl acetal into a reactor to react with 3-amino-6-chloropyridazine, thereby obtaining an N, N-dimethyl-N'-3-(6-chloro-pyridazine)yl-formamidine intermediate; 2, adding a solvent into the N, N-dimethyl-N'-3-(6-chloro-pyridazine)yl-formamidine intermediate obtained in the step 1, mixing, adding bromoacetonitrile, reacting, adding alkali liquor, standing, separating out solid, and filtering to obtain a solid mixture, 3, completely dissolving the solid mixture obtained in the step 4 in ethyl acetate, washing with water and saturated edible salt water, drying, filtering, and removing ethyl acetate to obtain a crude product of 6-chloroimidazo[1, 2-b]pyridazine-3-carbonitrile, and 4, recrystallizing the crude product of the 6-chloroimidazo[1, 2-b]pyridazine-3-carbonitrile, and filtering to obtain a pure product of the 6-chloroimidazo[1, 2-b] pyridazine-3-carbonitrile. The method is short in overall process time, and the obtained product is stable in quality and high in purity.

TGF-Beta Inhibitors

Disclosed are imidazole and thiazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, A, Z, R1 and R′ are as described herein. In certain embodiments, a compound disclosed herein inhibits TGF-β, and can be used to treat disease by blocking TGF-β signaling.

IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS

There is provided compounds of formula (I): wherein Z, M, R1, X, R3, R4 and R5 have meanings given in the description, an pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protei kinase (e.g. a PIM family kinase or PI3-K) is desired and/or required, an particularly in the treatment of cancer.